Isoniazid Prevention Therapy for HIV Positive Patients

Size: px
Start display at page:

Download "Isoniazid Prevention Therapy for HIV Positive Patients"

Transcription

1 Isoniazid Prevention Therapy for HIV Positive Patients Increasing Tuberculosis Prevention for HIV-Patients in Ethiopia QuickTime and a decompressor are needed to see this picture. Ashok Reddy, MD University of Washington

2 Presentation TB risk among HIV+ patients TB/HIV data at Gondar University Isoniazid Preventive Therapy (IPT) in HIV+ patients Challenges

3 The Global Burden of TB New Cases Deaths Total TB Cases 9.4 million 1.3 million MDR TB Cases 511, ,000 XDR TB Cases 50,000 30,000 HIV related TB accounts for 1.4 million cases, approximately 15% of all TB cases Globally an estimated 2 billion people have latent TB WHO Global TB Report 2009

4 Burden of HIV Associated TB Tuberculosis is #1 cause of death in HIV patients Incidence of TB doubled in Africa between , approx 149 to 343 cases per 100,000 Autopsy study from Botswana reported that 30-40% of HIV-infected adults die from tuberculosis Ethiopia has 8th highest burden of TB

5 Where is Gondar? QuickTime and a decompressor are needed to see this picture. NOT the Fictional Kingdom in the Lord of the Rings

6 Where is Gondar? Gondar QuickTime and a decompressor are needed to see this picture. QuickTime and a decompressor are needed to see this picture.

7 Gondar University -- TB Clinic # of TB #HIV+ #HIV- #undocumented #ART Jan Feb March April May June No data July August Sept Oct Nov Dec Total % of new TB pts who are HIV pos (# is likely higher) : 251/367= 68.3% Most disturbing is that >43% of pts getting TB medications do not have a documented test

8 Gondar University -- ART Clinic Total Enrolled On TB Rx Started after HAART Started before HAART Jan Feb March April May June July August Sept Oct Nov Dec TOTAL Prevalence Rate (#cases/population): 5.3%

9 TB/HIV Co-Infection Havlir, D. V. et al. JAMA 2008;300:

10 Combating Epidemic of TB/HIV Co-Infection WHO/STOP TB commission (3 I s) Intensified TB Screening among HIV pts Provision of Isoniazid Preventive Therapy (IPT) TB infection Control The number of HIV infected persons reported to have been screened for TB was less than 1% while IPT was reported to have been provided to less than 0.1% of eligible persons in 2006.

11 Data on IPT in HIV+ Patients Figure 1. Efficacy of tuberculosis (TB [includes confirmed, probable, and possible active cases of TB]) preventive therapy (with any drug), compared with placebo, in reducing the incidence of active TB. Death denotes death due to all causes. CI, confidence interval; PPD, purified protein derivative; PPD unknown, unknown PPD status; +, positive;, negative. A relative risk of <1 favors treatment. Copyright Cochrane Collaboration; adapted with permission from [11]. Woldehanna and Volmink, Cochrane Review 2006

12 Durability of IPT in HIV pts Protection can be detected from 18 months to 4 yrs (Havlir JAMA 2008) Zambia study demonstrates that protection begins to wane after one year (Mwinga AIDS 1998) IPT strategies may not provide protection from re-infection in endemic areas

13 Effect of IPT + ART in Brazil Exposure category Person-Years TB cases IR (per 100 PYs) IRR Naïve 3, HAART only 11, IPT only Both 1, TOTAL 17, ( ) 1.91 ( ) 1.27 ( ) 0.80 ( ) 2.28 ( ) ( ) 0.32 ( ) 0.20 ( ) Golub et al., AIDS, 2007

14 Effect of IPT + ART in S. Africa Exposure Category TB cases Person-Years IR (95% CI) IRR Naive ( ) 1.0 (Ref) HAART only ( ).65 (.46-91) IPT only ( ).73 ( ) IPT & HAART ( ) 0.15 ( ) Golub et al., AIDS, 2009

15 Challenges of IPT Rule out Active Tuberculosis Resistance/Adherence Complicated and Costly Toxicity

16 Rule out Active Tuberculosis South Africa study screening of two or more symptoms (WL, Cough, NS, Fever) had 100% sen/88% spec (Mohammed, Int J Tuber Lung Dis 2003) Uganda study published a screening tool in 2009; (Were, Int J Tuber Lung Dis 2009) 1995 participants, the presence of any one of the following had a 99% sen/66% spec: Cough > 3 wks (OR 37.9; %CI) Fever > 1 month (OR 34.1; ) Weight loss (OR 51.2; ) Night Sweats (OR 21.9; 12-37) BMI <18 (OR 7.2; 4-12) Lymphadenopathy (OR 4.0; ) Asymptomatic HIV-infected pts cxray, 1/563 was dx w/tb (Mosimaneotsile, Lancet 2003)

17 Resistance In a meta-analysis of 13 IPT trials, including both HIV infected and non-infected, there was low risk in the development of resistance (RR 1.45, CI 95% ) (Balcell EID 2006) Standard treatment was effective in treating INHr TB (Nolan Int J Tuber Lung Dis 2002) Tanzania, 87% of pts eligible for IPT completed 9 month course (Munseri PJ, Int J Tuber Lung Dis 2008)

18 Complicated and Costly Preventing one case of TB is cheaper than treatment of active case TST testing in HIV+ pts in resource-limited setting (Swaminathan Int J Tuber Lung Dis 2008) Sens 74%, Spec 69% CD4 count < 100, TST fails to detect more than half Even pts CD4 > 500 decreased rate TST Operational research on TST Uganda 19% of pts did not return at appropriate time Thailand 86% of doctors LTBI tx did not perform TST testing

19 Toxicity INH-associated complications include anorexia, N/V, dark urine, icterus, fever, rash, and neuro Uganda RCT 3/1000 stopped with adverse event (Whalen NEJM 1997; 337:801) S. Africa, ART cohort, IPT was not associated with higher risk of hepatotoxicity (Hoffmann AIDS 2007) Monitor LTBI (baseline, 1 month)

20 Conclusion HIV has fueled the epidemic of tuberculosis; these diseases are so intertwined that prevention and care of one must be tied to the other IPT offers an effective strategy to decrease the burden of tuberculosis in HIV+ pts This intervention could be added into the framework of current Ethiopian ART clinics

21 Acknowledgements ITECH Clinical Team ITECH Gondar Data Team UW Dept of Medicine Dr. Scott Barnhart Dr. Judd Walson

22 Future TB Ward in Gondar

23 IPT in Children As of 2009, only one RCT of HIV-infected children and IPT Marked reduction of TB incidence 4% vs 10% in placebo No data on durability or long-term adverse events No information on IPT on children on ART

24 Balcells et al., EID 2006 Resistance

25 Effect of INH resistance on outcomes of treatment for active TB Failure Died Default/ transfer Success Drug-susceptible 2% 2% 11% 85% IHN-resistant (any) 4% 2% 12% 82% RIF-resistant (any) 11% 2% 13% 73% JAMA 2000;283:

26 CONTRAINDICATIONS OF IPT 1. Active tuberculosis. 2. Symptoms compatible with tuberculosis, even if the diagnosis of TB cannot be confirmed. 3. Abnormal chest x-ray. 4. Active hepatitis (chronic or acute). Known or reported high daily alcohol consumption. 5. Prior allergy or intolerance to Isoniazid. 6. Pregnancy.

27 Secondary Prevention of IPT 3 studies have shown a benefit of IPT following treatment of active TB in HIV+ patients Incidence Rate Ratios & 95% CI Reference Haller (1999) Fitzgerald (2000) Churchyard (2002) Woldehanna and Volmink, Cochrane Review 2006

TB prevention studies in PLHIV: recent updates and what can they tell us for the future?

TB prevention studies in PLHIV: recent updates and what can they tell us for the future? TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working

More information

Overview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions

Overview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions 202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months

More information

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations Workshop to accelerate the implementation of the Three Is for HIV/TB and earlier initiation of ART in Southern Africa, March 14-18, 2011, Johannesburg, South Africa. The New WHO guidelines on intensified

More information

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific Thuy Le, MD DPhil Duke University School of Medicine, USA Oxford University Clinical Research Unit Hospital

More information

Isoniazid preventive therapy for HIV+:

Isoniazid preventive therapy for HIV+: Isoniazid preventive therapy for HIV+: Controversial topics Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Risk of TB disease after

More information

Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI

Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical

More information

The role of ART and IPT in TB prevention: Latest updates

The role of ART and IPT in TB prevention: Latest updates The role of ART and IPT in TB prevention: Latest updates Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University Consortium to Respond Effectively To the AIDS-TB Epidemic (CREATE)

More information

TB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD

TB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD TB Prevention in PLHIV: Options Other Than Isoniazid Johns Hopkins Center for Tuberculosis Richard E. Chaisson, MD Research Johns Hopkins University Center for Tuberculosis Research Consortium to Respond

More information

Time to implement: WHO guidelines on TB Preventive Treatment

Time to implement: WHO guidelines on TB Preventive Treatment Time to implement: WHO guidelines on TB Preventive Treatment WHO End TB Strategy TARGETS: 90% reduction of deaths and 80% reduction in incidence by 2030 Early diagnosis Integrated, of TB including universal

More information

IPT IMPLEMENTATION- SWAZILAND EXPERIENCE

IPT IMPLEMENTATION- SWAZILAND EXPERIENCE IPT IMPLEMENTATION- SWAZILAND EXPERIENCE Gugu Mchunu-National TB/HIV coordinator Programmatic Management of Latent TB infection consultation meeting Seoul, Republic of Korea,27-28 APRIL,2016 TB Epidemiology

More information

WHO Guidelines for IPT and ICF

WHO Guidelines for IPT and ICF WHO Guidelines for IPT and ICF Reuben Granich HIV/AIDS Department World Health Organization Haileyesus Getahun STOP TB Department World Health Organization Outline Background Evidence Recommendations Adults

More information

Diagnosis & Management of Latent TB Infection

Diagnosis & Management of Latent TB Infection Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,

More information

Tuberculosis Screening and IPT: Experience from India

Tuberculosis Screening and IPT: Experience from India Tuberculosis Screening and IPT: Experience from India Dr B.B.Rewari WHO National consultant Care, Support and Treatment National Programme Officer (ART) National AIDS Control Organization New Delhi-110001,

More information

Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children. Réghana Taliep

Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children. Réghana Taliep Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children Réghana Taliep Background Tuberculosis (TB) is a common complication and leading cause of death in HIV infection HIV is the strongest

More information

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key

More information

Issues in TB Drug Development: TB/HIV

Issues in TB Drug Development: TB/HIV Issues in TB Drug Development: TB/HIV Open Forum Gavin Churchyard 18 th August 2010 Presentation outline TB/HIV Epidemiology clinical aspects HIV associated TB Drug-Drug interactions Immunotherapy Latent

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Controlling TB in the era of HIV

Controlling TB in the era of HIV Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population

More information

Ongoing research on LTBI treatment and IMPAACT4TB

Ongoing research on LTBI treatment and IMPAACT4TB Ongoing research on LTBI treatment and IMPAACT4TB GJ Churchyard MBBCh (WITS), FCP (SA), FRCP (Edin), MMED (Int Med), PhD (WITS) 1 st September 2017 Who and when? PLHIV Household contacts High risk communities

More information

Table S1: Summary Table: Assessment of Individual Studies by Outcome

Table S1: Summary Table: Assessment of Individual Studies by Outcome Table S1: Summary Table: Assessment of Individual Studies by Outcome Study Characteristics Citation Mortality Akolo, C., et 2010. 1 Bucher, H.C., et 1999. 2 Study Design (e.g., RCT) Country, Study Period

More information

hiv & aids treatment in practice

hiv & aids treatment in practice hiv & aids treatment in practice Time for clear and simple messages about delivering isoniazid preventive therapy (IPT) This HATIP looks at the evidence supporting recent advocacy efforts to increase access

More information

Treatment of Latent TB Infection (LTBI)

Treatment of Latent TB Infection (LTBI) Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious

More information

Tuberculosis and HIV: key issues in diagnosis and management

Tuberculosis and HIV: key issues in diagnosis and management Tuberculosis and HIV: key issues in diagnosis and management Julian Elliott Infectious Diseases Unit, Alfred Hospital Centre for Population Health, Burnet Institute julian.elliott@alfred.org.au Outline

More information

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality

A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality Soumya Swaminathan,, PA Menon,, P Venkatesan et al Indian Council of Medical

More information

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG PEOPLE LIVING WITH HIV AND SILICOSIS IN SOUTH AFRICA

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG PEOPLE LIVING WITH HIV AND SILICOSIS IN SOUTH AFRICA GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG PEOPLE LIVING WITH HIV AND SILICOSIS IN SOUTH AFRICA Page 1 of 17 TABLE OF CONTENT 1 BACKGROUND... 4 2 TB, HIV AND SILICOSIS... 4 2.1 TB PREVENTIVE

More information

Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs

Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego

More information

Clinical Trials Lecture 4: Data analysis

Clinical Trials Lecture 4: Data analysis Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis

More information

Investing for Impact

Investing for Impact Global Fund Strategic Framework: Investing for Impact M&E: Capturing data to improve services Workshop to Scale Up the Implementation of Collaborative TB/HIV Activities in Africa 10-11 April, 2013; Maputo,

More information

EVALUATION OF ISONIAZID PREVENTIVE THERAPY POLICY

EVALUATION OF ISONIAZID PREVENTIVE THERAPY POLICY REVIEW ARTICLE. EVALUATION OF ISONIAZID PREVENTIVE THERAPY POLICY Bhavesh Modi 1, Paresh Dave 2 1 MPH Student, John Hopkins University, USA 2 Additional Director, Health & Family Welfare Department, Govertment

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic An International Research Partnership Supported by the Bill and Melinda Gates Foundation http://www.tbhiv-create.org Overview What is

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition

More information

Programmatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.

Programmatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD. Programmatic management of latent TB infection: Global perspective and updates Haileyesus Getahun, MD, MPH, PhD. What is latent TB infection? A state of persistent immune response to stimulation by Mycobacterium

More information

The Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam

The Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam The Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam K.H. Truong 1, H.T. Nguyen 2, X. Gao 3, Y. Hu 2,3, J. Harwell 2,3,

More information

IPT Policy Review South Africa. WHO TB/HIV Working Group meeting

IPT Policy Review South Africa. WHO TB/HIV Working Group meeting IPT Policy Review South Africa WHO TB/HIV Working Group meeting Outline Background Policy Environment Policy and Guidelines TB/HIV Collaboration Policy development process BACKGROUND Population: 53 Million

More information

Intensified TB Case Finding among HIV-infected Persons in Resource-limited Settings

Intensified TB Case Finding among HIV-infected Persons in Resource-limited Settings Intensified TB Case Finding among HIV-infected Persons in Resource-limited Settings Kevin Cain, MD Jay Varma, MD Division of Tuberculosis Elimination Centers for Disease Control and Prevention Need for

More information

State of the State in TB Control

State of the State in TB Control State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)

More information

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative

More information

HIV Clinicians Society Conference TB/HIV Treatment Cascade

HIV Clinicians Society Conference TB/HIV Treatment Cascade HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats

More information

Screening and management of latent TB Infection Gerry Davies

Screening and management of latent TB Infection Gerry Davies Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

Global Burden of Respiratory Disease Lessons from Afar Scott Barnhart, MD, MPH June 18, 2010

Global Burden of Respiratory Disease Lessons from Afar Scott Barnhart, MD, MPH June 18, 2010 Global Burden of Respiratory Disease Lessons from Afar Scott Barnhart, MD, MPH June 18, 2010 Scott Barnhart, MD, MPH June 18, 2010 Three Goals An Overview of the global burden of respiratory disease relative

More information

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the

More information

Latent tuberculosis infection

Latent tuberculosis infection EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent

More information

Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre

Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Overview The problem Treating active TB does not seem to be enough The solution:

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people

More information

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis among people living with HIV Somya Gupta, Taiwo Abimbola, Anand Date, Amitabh B. Suthar, Rod Bennett, Nalinee Sangrujee, Reuben

More information

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to: New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to

More information

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the

More information

Successes and remaining barriers to routine TB screening and implementation of IPT in Cambodia

Successes and remaining barriers to routine TB screening and implementation of IPT in Cambodia Successes and remaining barriers to routine TB screening and implementation of IPT in Cambodia Mean Chhi Vun, MD, MPH NCHADS Director mchhivun@nchads.org Scaling up the implementation of the TB/HIV collaborative

More information

WHERE DO WE GO FROM HERE?

WHERE DO WE GO FROM HERE? WHERE DO WE GO FROM HERE? WHAT WILL BE REQUIRED TO ACHIEVE ZERO DEATHS FROM TUBERCULOSIS? SALMAAN KESHAVJEE, MD, PHD, SCM HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2013 Case 1: 52 y/o male Born in the Pacific Islands; some travel in

More information

Isoniazid Preventive Therapy (IPT)

Isoniazid Preventive Therapy (IPT) Isoniazid Preventive Therapy (IPT) Josefina Cadorna-Carlos, M.D. Professor of Pediatrics U E R M M M C Objectives 1. Define IPT. 2. Discuss the indications for IPT. 3. Present RCT s for IPT (6H vs 9H).

More information

HIV/TB Co infection TB Clinical Intensive October 11, 2018

HIV/TB Co infection TB Clinical Intensive October 11, 2018 HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital

More information

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations

More information

TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011

TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant

More information

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES

More information

Background and Rationale for TB Infection Control

Background and Rationale for TB Infection Control Background and Rationale for TB Infection Control Henry M. Blumberg, M.D. Professor of Medicine and Epidemiology Program Director, Div. of Infectious Diseases Emory University School of Medicine and Hospital

More information

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan 17 th Annual Conference, The Union-North American Region, Vancouver, Canada. 28 February 2013 Farhana Amanullah Director

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with

More information

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation

More information

Treatment as Prevention

Treatment as Prevention Optimizing the Impact of ART Treatment as Prevention A Made-in-BC Strategy to End the AIDS Pandemic Julio Montaner, OC, OBC, MD Professor of Medicine and Head, Division of AIDS, University of British Columbia

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information

Errors in Dx and Rx of TB

Errors in Dx and Rx of TB Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a

More information

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten

More information

Latent TB Infection Treatment

Latent TB Infection Treatment Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None

More information

Latent TB Infection (LTBI) Strategies for Detection and Management

Latent TB Infection (LTBI) Strategies for Detection and Management Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu

More information

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey

More information

Presented by Leigh Snyman April 2017

Presented by Leigh Snyman April 2017 Presented by Leigh Snyman April 2017 Overview Definition of Palliative Care Case based discussion Take home messages What is Palliative Care? WHO Definition of Palliative Care: Palliative care is an approach

More information

IPT and ICF Guidelines Update

IPT and ICF Guidelines Update IPT and ICF Guidelines Update Reuben Granich HIV/AIDS Department World Health Organization Haileyesus Getahun STOP TB Department World Health Organization TB related questions Background Guidelines Review

More information

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.

More information

Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection

Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Krista Powell, MD, MPH Co-Project Officer, National Surveillance for Severe Adverse Events Associated with LTBI Treatment Lead,

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB and Diabetes Barbara Seaworth, MD July 19, 2012 Barbara Seaworth, MD, FIDSA, FACP has the following disclosures to make: Has an advisory

More information

SOUTH AFRICA S TB BURDEN - OVERVIEW

SOUTH AFRICA S TB BURDEN - OVERVIEW SOUTH AFRICA S TB BURDEN - OVERVIEW Dr Aaron Motsoaledi, MP: Chairperson of the Board, Stop TB Partnership Minister of Health, South Africa 31 January 2014, Cape Town South Africa s TB Burden Global TB

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

INTENSIFIED TB CASE FINDING

INTENSIFIED TB CASE FINDING INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities

More information

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and

More information

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International

More information

Non-rifampin rifamycins in TB/HIV

Non-rifampin rifamycins in TB/HIV Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent

More information

TOG The Way Forward

TOG The Way Forward TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till

More information

Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review

Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive

More information

Northwestern Polytechnic University

Northwestern Polytechnic University Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions

More information

Drug and Health Care Delivery: A perspective from Cambodia and Ethiopia

Drug and Health Care Delivery: A perspective from Cambodia and Ethiopia Drug and Health Care Delivery: A perspective from Cambodia and Ethiopia Sok Thim and Anne Goldfeld Cambodian Health Committee/ Global Health Committee Immune Disease Institute Harvard Medical School November

More information

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!

More information

PROGRESS ON IMPLEMENTATION OF THE 3Is IN SOUTH AFRICA. Yogan Pillay Deputy Director General Strategic Health Programmes South Africa

PROGRESS ON IMPLEMENTATION OF THE 3Is IN SOUTH AFRICA. Yogan Pillay Deputy Director General Strategic Health Programmes South Africa PROGRESS ON IMPLEMENTATION OF THE 3Is IN SOUTH AFRICA Yogan Pillay Deputy Director General Strategic Health Programmes South Africa South Africa Population: 49 320 500 Mil Province Population 2009 mid

More information

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations

More information

Transmission of DS-TB and MDR-TB. C. Robert Horsburgh, Jr. Boston University School of Public Health

Transmission of DS-TB and MDR-TB. C. Robert Horsburgh, Jr. Boston University School of Public Health Transmission of DS-TB and MDR-TB C. Robert Horsburgh, Jr. Boston University School of Public Health Outline Epidemiologic factors in transmission Ability of the transmitter to transmit Susceptibility of

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009 2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in

More information

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No

More information

Supplement 2: Extracted studies

Supplement 2: Extracted studies Supplement 2: Extracted studies First author Journal Year Participants Country of study Drugs compared Participants Hepatotoxicity extractable? Development of active TB? Agarwal (42) Urology and Nephrology

More information